Compass Therapeutics prices $120 million public offering at $3 per share

Compass Therapeutics Inc. (NASDAQ: CMPX) announced the pricing of an underwritten public offering of 33.29 million shares of common stock at $3.00 per share and pre-funded warrants to purchase up to 6.71 million shares at $2.9999 per warrant.

The gross proceeds from the offering are expected to be approximately $120 million before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions.

The company has granted underwriters a 30-day option to purchase up to 6 million additional shares of common stock at the public offering price, less the underwriting discount.

Compass intends to use the net proceeds to conduct preparations for commercial readiness, fund research and clinical development of its product candidates, and for general corporate purposes.

Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are serving as lead managers, while Ladenburg Thalmann and D. Boral Capital are acting as co-managers.

The clinical-stage biopharmaceutical company develops antibody-based therapeutics for oncology applications. The offering is being conducted under a shelf registration statement filed with the Securities and Exchange Commission on August 30, 2024, which was declared effective on September 6, 2024.

You May Also Be Interested In

• TryHard Holdings regains Nasdaq compliance after reverse stock split
• Tenon Medical prices $3M private placement with institutional investor
• Mint Incorporation closes $2.5M registered direct offering